big number
112,000. That’s how many new cases of melanoma are diagnosed in the U.S. each year, with about 8,510 people expected to die of melanoma, according to the American Cancer Society. The group warned that lighter skin color is a major risk factor and that risk increases as people age.
Read more North Korea Denounces U.S.-South Korea Military Drill Ignoring Trump’s Overtures To Kim
surprising fact
The lowest level for Moderna’s stock came during its first trading session this year, dropping to $29.81 on Jan. 2 before surging nearly 300% to its premarket value on Wednesday.
Read more Trump Pauses New 50% Tariffs On Canada Claiming Last-Minute Deal
key background
Wall Street had anticipated results from Moderna’s latest mRNA vaccine, which have come under fire from Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy, a noted vaccine skeptic who criticized mRNA COVID-19 vaccines like Moderna’s, has said he would cancel contracts and grants worth nearly $500 million to develop such vaccines. Leerink Partners analyst Mani Foroohar wrote in June that results from Moderna’s late-stage trial would mark a make-or-break event for its stock, with expectations for the experimental medication to potentially work across multiple types of cancer. Merck and Moderna have said they are studying the vaccine in several trials of other tumors, like non-small cell lung cancer and bladder cancer.
Read more Debbie Wasserman Schultz Wins In Florida Primary For Heavily Black District
further reading
ForbesFDA Approves First mRNA Flu Vaccine For Older AdultsBy Siladitya Ray